Due to covid, non-urgent operations were all ceased in many states - even with that non-covid testing increased by 2% which in itself is impressive.
They had non-covid rev of 258.2m$ last half. Medlab had no contribution in this.
EBIT margin came at 35.5% - a lot has to do with covid testing. Before medlab acquisition that was around 21%.
Medlab acquisition will give them scale, margin for non-covid revenue should be around 23-25%. Lets assume 23%.
Medlab had FY21 rev of 93m$. They are expecting 20m$ of EBIT from medlab acquisition for whole year from FY23.
Assuming 2.8% growth again for non-covid rev gives: 265m$ for the half
@ EBIT margin of 23% [taking the lower value]: 60.95m$ for the half.
They used to pay around 12m$ as interest payments - since now they have paid off their loan - inluding 4m$ a year anyways to count for small loans etc; that still gives 8m$ of savings which will go into EBIT increase.
extrapolating to the whole year, EBIT: 149.9 ~ 150m$ EBIT from non covid testing for the whole year. 30% tax: 45m$
NPAT: 105m$
This is with ZERO covid rev:
PE @ 4.73: 9.
Still ridiculously cheap for pretty much all medicare covered payments.
Add in all the revenue from covid testing
- WA today had more than 1000 cases - its like a virgin territory for covid. there will be plenty of rev to me made.
- still plenty of cases in eastern states.
- Covid testing will stay FOREEVER! - scale will change.
- international borders will open and taht will bring more cases.
- any new variant and it will go gangbusters.
- NON-covid revenue above is very conservative. It will definitely be more since now there will be no restrictions.
- generally australian population is getting older - more pathology testing.
PS: how is ur rocket on APX going?
- Forums
- ASX - By Stock
- ACL
- Ann: Media Release - 1H22 Financial Results
Ann: Media Release - 1H22 Financial Results, page-6
-
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
Add ACL (ASX) to my watchlist
(20min delay)
|
|||||
Last
$3.63 |
Change
-0.110(2.94%) |
Mkt cap ! $732.6M |
Open | High | Low | Value | Volume |
$3.71 | $3.76 | $3.62 | $2.650M | 723.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 7666 | $3.62 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$3.65 | 7000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 10289 | 3.600 |
1 | 142 | 3.590 |
1 | 3000 | 3.570 |
1 | 7000 | 3.520 |
2 | 2500 | 3.500 |
Price($) | Vol. | No. |
---|---|---|
3.730 | 7762 | 1 |
3.740 | 1350 | 1 |
3.750 | 14483 | 3 |
3.770 | 3000 | 1 |
3.800 | 4775 | 4 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
ACL (ASX) Chart |